{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:00:49Z","timestamp":1794013249501,"version":"4.8.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00428-025-04379-w","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:24:06Z","timestamp":1766503446000},"page":"173-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The evolving roles of pathologists in paragangliomas and pheochromocytomas"],"prefix":"10.1007","volume":"488","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0469-2801","authenticated-orcid":false,"given":"Ozgur","family":"Mete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-9081","authenticated-orcid":false,"given":"C. Christofer","family":"Juhlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"4379_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S et al (2022) Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol 33:115\u2013154. https:\/\/doi.org\/10.1007\/s12022-022-09708-2","journal-title":"Endocr Pathol"},{"key":"4379_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol 33:6\u201326. https:\/\/doi.org\/10.1007\/s12022-022-09703-7","journal-title":"Endocr Pathol"},{"key":"4379_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","volume":"33","author":"O Mete","year":"2022","unstructured":"Mete O, Asa SL, Gill AJ et al (2022) Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol 33:90\u2013114. https:\/\/doi.org\/10.1007\/s12022-022-09704-6","journal-title":"Endocr Pathol"},{"key":"4379_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12022-024-09844-x","volume":"35","author":"O Mete","year":"2024","unstructured":"Mete O (2024) Insights into biologic evolution of grade 3 neuroendocrine tumors reflect classification challenges. Endocr Pathol 35:311\u2013312. https:\/\/doi.org\/10.1007\/s12022-024-09844-x","journal-title":"Endocr Pathol"},{"key":"4379_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12105-022-01435-8","volume":"16","author":"O Mete","year":"2022","unstructured":"Mete O, Wenig BM (2022) Update from the 5th edition of the world health organization classification of head and neck tumors: overview of the 2022 WHO classification of head and neck neuroendocrine neoplasms. Head Neck Pathol 16:123\u2013142. https:\/\/doi.org\/10.1007\/s12105-022-01435-8","journal-title":"Head Neck Pathol"},{"key":"4379_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/PAS.0000000000002009","volume":"47","author":"SL Asa","year":"2023","unstructured":"Asa SL, Mete O, Sch\u00fcller U et al (2023) Cauda equina neuroendocrine tumors: distinct epithelial neuroendocrine neoplasms of spinal origin. Am J Surg Pathol 47:469\u2013475. https:\/\/doi.org\/10.1097\/PAS.0000000000002009","journal-title":"Am J Surg Pathol"},{"key":"4379_CR7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s12022-024-09840-1","volume":"35","author":"FM Dogukan","year":"2024","unstructured":"Dogukan FM, Mete O (2024) Cauda equina neuroendocrine tumors with ganglioneuromatous elements are best classified as composite gangliocytoma\/neuroma and neuroendocrine tumor (COGNET). Endocr Pathol 35:453\u2013456. https:\/\/doi.org\/10.1007\/s12022-024-09840-1","journal-title":"Endocr Pathol"},{"key":"4379_CR8","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JWM Lenders","year":"2014","unstructured":"Lenders JWM, Duh Q-Y, Eisenhofer G et al (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:1915\u20131942. https:\/\/doi.org\/10.1210\/jc.2014-1498","journal-title":"J Clin Endocrinol Metab"},{"key":"4379_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S2213-8587(23)00038-4","volume":"11","author":"D Ta\u00efeb","year":"2023","unstructured":"Ta\u00efeb D, Wanna GB, Ahmad M et al (2023) Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. Lancet Diabetes Endocrinol 11:345\u2013361. https:\/\/doi.org\/10.1016\/S2213-8587(23)00038-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4379_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2024.101957","volume":"39","author":"C Pamporaki","year":"2025","unstructured":"Pamporaki C, Casey RT (2025) Current views on paediatric phaeochromocytoma and paraganglioma with a focus on newest guidelines. Best Pract Res Clin Endocrinol Metab 39:101957. https:\/\/doi.org\/10.1016\/j.beem.2024.101957","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"4379_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1507\/endocrj.EJ24-0584","volume":"72","author":"N Kimura","year":"2025","unstructured":"Kimura N, Muroya K, Yonamine M et al (2025) Clinicopathological and genomic analysis of pediatric pheochromocytoma and sympathetic paraganglioma. Endocr J 72:399\u2013412. https:\/\/doi.org\/10.1507\/endocrj.EJ24-0584","journal-title":"Endocr J"},{"key":"4379_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.5146\/tjpath.2024.13681","volume":"40","author":"CC Juhlin","year":"2024","unstructured":"Juhlin CC, Mete O (2024) Hot trends in pheochromocytoma and paraganglioma: are we getting closer to personalized dynamic prognostication? Turk Patoloji Derg 40:143\u2013148. https:\/\/doi.org\/10.5146\/tjpath.2024.13681","journal-title":"Turk Patoloji Derg"},{"key":"4379_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2024.101958","volume":"38","author":"O Mete","year":"2024","unstructured":"Mete O, Juhlin CC (2024) Recent progress in the pathologic classification of pheochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab 38:101958. https:\/\/doi.org\/10.1016\/j.beem.2024.101958","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"4379_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s12022-013-9296-1","volume":"25","author":"AC Millar","year":"2014","unstructured":"Millar AC, Mete O, Cusimano RJ et al (2014) Functional cardiac paraganglioma associated with a rare SDHC mutation. Endocr Pathol 25:315\u2013320. https:\/\/doi.org\/10.1007\/s12022-013-9296-1","journal-title":"Endocr Pathol"},{"key":"4379_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/jcm7090280","volume":"7","author":"SL Asa","year":"2018","unstructured":"Asa SL, Ezzat S, Mete O (2018) The diagnosis and clinical significance of paragangliomas in unusual locations. J Clin Med 7:280. https:\/\/doi.org\/10.3390\/jcm7090280","journal-title":"J Clin Med"},{"key":"4379_CR16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s12022-017-9485-4","volume":"28","author":"O Mete","year":"2017","unstructured":"Mete O, Essa A, Bramdev A et al (2017) MEN2 syndrome-related medullary thyroid carcinoma with focal tyrosine hydroxylase expression: does it represent a hybrid cellular phenotype or functional state of tumor cells? Endocr Pathol 28:362\u2013366. https:\/\/doi.org\/10.1007\/s12022-017-9485-4","journal-title":"Endocr Pathol"},{"key":"4379_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s12022-023-09784-y","volume":"34","author":"A Vanoli","year":"2023","unstructured":"Vanoli A, Messina A, Gallotti A et al (2023) Well-differentiated neuroendocrine tumor of the gallbladder with paraganglioma-like features: a potential mimicker of gallbladder paraganglioma. Endocr Pathol 34:358\u2013360. https:\/\/doi.org\/10.1007\/s12022-023-09784-y","journal-title":"Endocr Pathol"},{"key":"4379_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12022-020-09645-y","volume":"31","author":"CC Juhlin","year":"2020","unstructured":"Juhlin CC, Zedenius J, H\u00f6\u00f6g A (2020) Clinical routine application of the second-generation neuroendocrine markers ISL1, INSM1, and secretagogin in neuroendocrine neoplasia: staining outcomes and potential clues for determining tumor origin. Endocr Pathol 31:401\u2013410. https:\/\/doi.org\/10.1007\/s12022-020-09645-y","journal-title":"Endocr Pathol"},{"key":"4379_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/biology10090874","volume":"10","author":"CC Juhlin","year":"2021","unstructured":"Juhlin CC (2021) Second-generation neuroendocrine immunohistochemical markers: reflections from clinical implementation. Biology 10:874. https:\/\/doi.org\/10.3390\/biology10090874","journal-title":"Biology"},{"issue":"8","key":"4379_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.mpdhp.2014.06.002","volume":"20","author":"T Hayashi","year":"2014","unstructured":"Hayashi T, Mete O (2014) Head and neck paragangliomas: what does the pathologist need to know? Diagn Histopathol 20(8):316\u2013325","journal-title":"Diagn Histopathol"},{"key":"4379_CR21","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.4158\/EP14093.CR","volume":"20","author":"R Leibowitz-Amit","year":"2014","unstructured":"Leibowitz-Amit R, Mete O, Asa SL et al (2014) Malignant pheochromocytoma secreting vasoactive intestinal peptide and response to sunitinib: a case report and literature review. Endocr Pract 20:e145-150. https:\/\/doi.org\/10.4158\/EP14093.CR","journal-title":"Endocr Pract"},{"key":"4379_CR22","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s12022-022-09730-4","volume":"33","author":"M Miyauchi","year":"2022","unstructured":"Miyauchi M, Akashi T, Furukawa A et al (2022) PHOX2B is a sensitive and specific marker for the histopathological diagnosis of pheochromocytoma and paraganglioma. Endocr Pathol 33:506\u2013518. https:\/\/doi.org\/10.1007\/s12022-022-09730-4","journal-title":"Endocr Pathol"},{"key":"4379_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s12022-022-09715-3","volume":"33","author":"S Uccella","year":"2022","unstructured":"Uccella S, Facco C, Chiaravalli AM et al (2022) Transcription factor expression in sinonasal neuroendocrine neoplasms and olfactory neuroblastoma (ONB): hyams\u2019 grades 1\u20133 ONBs expand the spectrum of SATB2 and GATA3-positive neoplasms. Endocr Pathol 33:264\u2013273. https:\/\/doi.org\/10.1007\/s12022-022-09715-3","journal-title":"Endocr Pathol"},{"key":"4379_CR24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s12022-021-09684-z","volume":"32","author":"SL Asa","year":"2021","unstructured":"Asa SL, Arkun K, Tischler AS et al (2021) Middle ear \u201cadenoma\u201d: a neuroendocrine tumor with predominant L cell differentiation. Endocr Pathol 32:433\u2013441. https:\/\/doi.org\/10.1007\/s12022-021-09684-z","journal-title":"Endocr Pathol"},{"key":"4379_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s12022-024-09803-6","volume":"35","author":"J Soukup","year":"2024","unstructured":"Soukup J, Manethova M, Stejskal V et al (2024) Hand2 immunohistochemistry in the diagnosis of paragangliomas and other neuroendocrine neoplasms. Endocr Pathol 35:14\u201324. https:\/\/doi.org\/10.1007\/s12022-024-09803-6","journal-title":"Endocr Pathol"},{"key":"4379_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5858\/arpa.2012-0551-OA","volume":"138","author":"O Mete","year":"2014","unstructured":"Mete O, Tischler AS, de Krijger R et al (2014) Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas. Arch Pathol Lab Med 138:182\u2013188. https:\/\/doi.org\/10.5858\/arpa.2012-0551-OA","journal-title":"Arch Pathol Lab Med"},{"key":"4379_CR27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12022-020-09655-w","volume":"32","author":"N Kimura","year":"2021","unstructured":"Kimura N (2021) Dopamine \u03b2-hydroxylase: an essential and optimal immunohistochemical marker for pheochromocytoma and sympathetic paraganglioma. Endocr Pathol 32:258\u2013261. https:\/\/doi.org\/10.1007\/s12022-020-09655-w","journal-title":"Endocr Pathol"},{"key":"4379_CR28","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s12022-021-09694-x","volume":"32","author":"N Kimura","year":"2021","unstructured":"Kimura N, Shiga K, Kaneko K-I et al (2021) Immunohistochemical expression of choline acetyltransferase and catecholamine-synthesizing enzymes in head-and-neck and thoracoabdominal paragangliomas and pheochromocytomas. Endocr Pathol 32:442\u2013451. https:\/\/doi.org\/10.1007\/s12022-021-09694-x","journal-title":"Endocr Pathol"},{"key":"4379_CR29","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/jmedgenet-2015-103218","volume":"52","author":"M Curr\u00e1s-Freixes","year":"2015","unstructured":"Curr\u00e1s-Freixes M, Inglada-P\u00e9rez L, Mancikova V et al (2015) Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients. J Med Genet 52:647\u2013656. https:\/\/doi.org\/10.1136\/jmedgenet-2015-103218","journal-title":"J Med Genet"},{"key":"4379_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12022-021-09675-0","volume":"32","author":"CC Juhlin","year":"2021","unstructured":"Juhlin CC (2021) Challenges in paragangliomas and pheochromocytomas: from histology to molecular immunohistochemistry. Endocr Pathol 32:228\u2013244. https:\/\/doi.org\/10.1007\/s12022-021-09675-0","journal-title":"Endocr Pathol"},{"key":"4379_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-020-09658-7","author":"TG Papathomas","year":"2021","unstructured":"Papathomas TG, Suurd DPD, Pacak K et al (2021) What have we learned from molecular biology of paragangliomas and pheochromocytomas? Endocr Pathol. https:\/\/doi.org\/10.1007\/s12022-020-09658-7","journal-title":"Endocr Pathol"},{"key":"4379_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1086\/321282","volume":"69","author":"D Astuti","year":"2001","unstructured":"Astuti D, Latif F, Dallol A et al (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69:49\u201354. https:\/\/doi.org\/10.1086\/321282","journal-title":"Am J Hum Genet"},{"key":"4379_CR33","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0111","volume":"31","author":"AI Kaplan","year":"2024","unstructured":"Kaplan AI, Dwight T, Luxford C et al (2024) SDHA-related phaeochromocytoma and paraganglioma: review and clinical management. Endocr Relat Cancer 31:e240111. https:\/\/doi.org\/10.1530\/ERC-24-0111","journal-title":"Endocr Relat Cancer"},{"key":"4379_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/his.13277","volume":"72","author":"AJ Gill","year":"2018","unstructured":"Gill AJ (2018) Succinate dehydrogenase (SDH)-deficient neoplasia. Histopathology 72:106\u2013116. https:\/\/doi.org\/10.1111\/his.13277","journal-title":"Histopathology"},{"key":"4379_CR35","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","volume":"23","author":"LJ Castro-Vega","year":"2014","unstructured":"Castro-Vega LJ, Buffet A, De Cubas AA et al (2014) Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet 23:2440\u20132446. https:\/\/doi.org\/10.1093\/hmg\/ddt639","journal-title":"Hum Mol Genet"},{"key":"4379_CR36","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/ng849","volume":"30","author":"IPM Tomlinson","year":"2002","unstructured":"Tomlinson IPM, Alam NA, Rowan AJ et al (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30:406\u2013410. https:\/\/doi.org\/10.1038\/ng849","journal-title":"Nat Genet"},{"key":"4379_CR37","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/ng.533","volume":"42","author":"Y Qin","year":"2010","unstructured":"Qin Y, Yao L, King EE et al (2010) Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 42:229\u2013233. https:\/\/doi.org\/10.1038\/ng.533","journal-title":"Nat Genet"},{"key":"4379_CR38","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1101\/gad.1648608","volume":"22","author":"S Schlisio","year":"2008","unstructured":"Schlisio S, Kenchappa RS, Vredeveld LCW et al (2008) The kinesin KIF1B\u03b2 acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 22:884\u2013893. https:\/\/doi.org\/10.1101\/gad.1648608","journal-title":"Genes Dev"},{"key":"4379_CR39","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/hmg\/ddt069","volume":"22","author":"I Comino-M\u00e9ndez","year":"2013","unstructured":"Comino-M\u00e9ndez I, de Cubas AA, Bernal C et al (2013) Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet 22:2169\u20132176. https:\/\/doi.org\/10.1093\/hmg\/ddt069","journal-title":"Hum Mol Genet"},{"key":"4379_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00109-014-1205-7","volume":"93","author":"C Yang","year":"2015","unstructured":"Yang C, Zhuang Z, Fliedner SMJ et al (2015) Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma\/paraganglioma-polycythemia. J Mol Med (Berl) 93:93\u2013104. https:\/\/doi.org\/10.1007\/s00109-014-1205-7","journal-title":"J Mol Med (Berl)"},{"key":"4379_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv053","volume":"107","author":"A Casc\u00f3n","year":"2015","unstructured":"Casc\u00f3n A, Comino-M\u00e9ndez I, Curr\u00e1s-Freixes M et al (2015) Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene. J Natl Cancer Inst 107:djv053. https:\/\/doi.org\/10.1093\/jnci\/djv053","journal-title":"J Natl Cancer Inst"},{"key":"4379_CR42","doi-asserted-by":"publisher","DOI":"10.1530\/JME-22-0167","volume":"70","author":"A Casc\u00f3n","year":"2023","unstructured":"Casc\u00f3n A, Calsina B, Monteagudo M et al (2023) Genetic bases of pheochromocytoma and paraganglioma. J Mol Endocrinol 70:e220167. https:\/\/doi.org\/10.1530\/JME-22-0167","journal-title":"J Mol Endocrinol"},{"key":"4379_CR43","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"Fishbein L, Leshchiner I, Walter V et al (2017) Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31:181\u2013193. https:\/\/doi.org\/10.1016\/j.ccell.2017.01.001","journal-title":"Cancer Cell"},{"key":"4379_CR44","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1210\/me.2010-0256","volume":"24","author":"E L\u00f3pez-Jim\u00e9nez","year":"2010","unstructured":"L\u00f3pez-Jim\u00e9nez E, G\u00f3mez-L\u00f3pez G, Leandro-Garc\u00eda LJ et al (2010) Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol 24:2382\u20132391. https:\/\/doi.org\/10.1210\/me.2010-0256","journal-title":"Mol Endocrinol"},{"key":"4379_CR45","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1158\/1078-0432.CCR-16-2250","volume":"23","author":"L Remacha","year":"2017","unstructured":"Remacha L, Comino-M\u00e9ndez I, Richter S et al (2017) Targeted exome sequencing of Krebs cycle genes reveals candidate cancer-predisposing mutations in pheochromocytomas and paragangliomas. Clin Cancer Res 23:6315\u20136324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2250","journal-title":"Clin Cancer Res"},{"key":"4379_CR46","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ajhg.2019.02.017","volume":"104","author":"L Remacha","year":"2019","unstructured":"Remacha L, Pirman D, Mahoney CE et al (2019) Recurrent germline DLST mutations in individuals with multiple pheochromocytomas and paragangliomas. Am J Hum Genet 104:651\u2013664. https:\/\/doi.org\/10.1016\/j.ajhg.2019.02.017","journal-title":"Am J Hum Genet"},{"key":"4379_CR47","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1158\/0008-5472.CAN-17-2463","volume":"78","author":"A Buffet","year":"2018","unstructured":"Buffet A, Morin A, Castro-Vega L-J et al (2018) Germline mutations in the mitochondrial 2-oxoglutarate\/malate carrier SLC25A11 gene confer a predisposition to metastatic paragangliomas. Cancer Res 78:1914\u20131922. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-2463","journal-title":"Cancer Res"},{"key":"4379_CR48","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/ERC-15-0099","volume":"22","author":"E Kim","year":"2015","unstructured":"Kim E, Rath EM, Tsang VHM et al (2015) Structural and functional consequences of succinate dehydrogenase subunit B mutations. Endocr Relat Cancer 22:387\u2013397. https:\/\/doi.org\/10.1530\/ERC-15-0099","journal-title":"Endocr Relat Cancer"},{"key":"4379_CR49","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1530\/ERC-19-0024","volume":"26","author":"J Crona","year":"2019","unstructured":"Crona J, Lamarca A, Ghosal S et al (2019) Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis. Endocr Relat Cancer 26:539\u2013550. https:\/\/doi.org\/10.1530\/ERC-19-0024","journal-title":"Endocr Relat Cancer"},{"key":"4379_CR50","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1210\/er.2017-00062","volume":"38","author":"J Crona","year":"2017","unstructured":"Crona J, Ta\u00efeb D, Pacak K (2017) New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification. Endocr Rev 38:489\u2013515. https:\/\/doi.org\/10.1210\/er.2017-00062","journal-title":"Endocr Rev"},{"key":"4379_CR51","doi-asserted-by":"publisher","first-page":"E1352","DOI":"10.1210\/jc.2013-4375","volume":"99","author":"J Welander","year":"2014","unstructured":"Welander J, Andreasson A, Juhlin CC et al (2014) Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 99:E1352-1360. https:\/\/doi.org\/10.1210\/jc.2013-4375","journal-title":"J Clin Endocrinol Metab"},{"key":"4379_CR52","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1093\/hmg\/dds374","volume":"21","author":"N Burnichon","year":"2012","unstructured":"Burnichon N, Buffet A, Parfait B et al (2012) Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet 21:5397\u20135405. https:\/\/doi.org\/10.1093\/hmg\/dds374","journal-title":"Hum Mol Genet"},{"key":"4379_CR53","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/ng.861","volume":"43","author":"I Comino-M\u00e9ndez","year":"2011","unstructured":"Comino-M\u00e9ndez I, Gracia-Azn\u00e1rez FJ, Schiavi F et al (2011) Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 43:663\u2013667. https:\/\/doi.org\/10.1038\/ng.861","journal-title":"Nat Genet"},{"key":"4379_CR54","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s00268-017-4320-0","volume":"42","author":"J Welander","year":"2018","unstructured":"Welander J, \u0141ysiak M, Brauckhoff M et al (2018) Activating FGFR1 mutations in sporadic pheochromocytomas. World J Surg 42:482\u2013489. https:\/\/doi.org\/10.1007\/s00268-017-4320-0","journal-title":"World J Surg"},{"key":"4379_CR55","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/978-3-030-54391-4_18","volume-title":"The spectrum of neuroendocrine neoplasia","author":"O Mete","year":"2021","unstructured":"Mete O, Hannah-Shmouni F, Kim R, Stratakis CA (2021) Inherited neuroendocrine neoplasms. In: Asa SL, La Rosa S, Mete O (eds) The spectrum of neuroendocrine neoplasia. Springer International Publishing, Cham, pp 409\u2013459."},{"key":"4379_CR56","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1440-1827.1991.tb01629.x","volume":"41","author":"A Yoshida","year":"1991","unstructured":"Yoshida A, Hatanaka S, Ohi Y et al (1991) Von Recklinghausen\u2019s disease associated with somatostatin-rich duodenal carcinoid (somatostatinoma), medullary thyroid carcinoma and diffuse adrenal medullary hyperplasia. Acta Pathol Jpn 41:847\u2013856. https:\/\/doi.org\/10.1111\/j.1440-1827.1991.tb01629.x","journal-title":"Acta Pathol Jpn"},{"key":"4379_CR57","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s12022-016-9460-5","volume":"28","author":"P Romanet","year":"2017","unstructured":"Romanet P, Guerin C, Pedini P et al (2017) Pathological and genetic characterization of bilateral adrenomedullary hyperplasia in a patient with germline MAX mutation. Endocr Pathol 28:302\u2013307. https:\/\/doi.org\/10.1007\/s12022-016-9460-5","journal-title":"Endocr Pathol"},{"key":"4379_CR58","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1200\/JCO.2010.32.2156","volume":"29","author":"RH Grogan","year":"2011","unstructured":"Grogan RH, Pacak K, Pasche L et al (2011) Bilateral adrenal medullary hyperplasia associated with an SDHB mutation. J Clin Oncol 29:e200-202. https:\/\/doi.org\/10.1200\/JCO.2010.32.2156","journal-title":"J Clin Oncol"},{"key":"4379_CR59","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00428-015-1755-2","volume":"466","author":"KG Hernandez","year":"2015","unstructured":"Hernandez KG, Ezzat S, Morel CF et al (2015) Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association. Virchows Arch 466:727\u2013732. https:\/\/doi.org\/10.1007\/s00428-015-1755-2","journal-title":"Virchows Arch"},{"key":"4379_CR60","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/PAT.0b013e32835f45c5","volume":"45","author":"O Mete","year":"2013","unstructured":"Mete O, Asa SL (2013) Precursor lesions of endocrine system neoplasms. Pathology 45:316\u2013330. https:\/\/doi.org\/10.1097\/PAT.0b013e32835f45c5","journal-title":"Pathology"},{"key":"4379_CR61","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12022-022-09710-8","volume":"33","author":"O Mete","year":"2022","unstructured":"Mete O, Erickson LA, Juhlin CC et al (2022) Overview of the 2022 WHO classification of adrenal cortical tumors. Endocr Pathol 33:155\u2013196. https:\/\/doi.org\/10.1007\/s12022-022-09710-8","journal-title":"Endocr Pathol"},{"key":"4379_CR62","doi-asserted-by":"publisher","first-page":"263","DOI":"10.5858\/arpa.2013-0520-RS","volume":"139","author":"C Cassol","year":"2015","unstructured":"Cassol C, Mete O (2015) Endocrine manifestations of von Hippel-Lindau disease. Arch Pathol Lab Med 139:263\u2013268. https:\/\/doi.org\/10.5858\/arpa.2013-0520-RS","journal-title":"Arch Pathol Lab Med"},{"key":"4379_CR63","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1210\/clinem\/dgaa957","volume":"106","author":"AJ Seabrook","year":"2021","unstructured":"Seabrook AJ, Harris JE, Velosa SB et al (2021) Multiple endocrine tumors associated with germline MAX mutations: multiple endocrine neoplasia type 5? J Clin Endocrinol Metab 106:1163\u20131182. https:\/\/doi.org\/10.1210\/clinem\/dgaa957","journal-title":"J Clin Endocrinol Metab"},{"key":"4379_CR64","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00428-023-03492-y","volume":"483","author":"J Costa","year":"2023","unstructured":"Costa J, J\u00e1come M, Souteiro P et al (2023) Composite pheochromocytoma of the adrenal gland-a review of published cases. Virchows Arch 483:267\u2013275. https:\/\/doi.org\/10.1007\/s00428-023-03492-y","journal-title":"Virchows Arch"},{"key":"4379_CR65","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.humpath.2009.12.005","volume":"41","author":"AJ Gill","year":"2010","unstructured":"Gill AJ, Benn DE, Chou A et al (2010) Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol 41:805\u2013814. https:\/\/doi.org\/10.1016\/j.humpath.2009.12.005","journal-title":"Hum Pathol"},{"key":"4379_CR66","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/jnci\/djab158","volume":"114","author":"K Hadrava Vanova","year":"2022","unstructured":"Hadrava Vanova K, Pang Y, Krobova L et al (2022) Germline SUCLG2 variants in patients with pheochromocytoma and paraganglioma. J Natl Cancer Inst 114:130\u2013138. https:\/\/doi.org\/10.1093\/jnci\/djab158","journal-title":"J Natl Cancer Inst"},{"key":"4379_CR67","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41379-019-0343-4","volume":"33","author":"J Favier","year":"2020","unstructured":"Favier J, Meatchi T, Robidel E et al (2020) Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma-a retrospective and prospective study. Mod Pathol 33:57\u201364. https:\/\/doi.org\/10.1038\/s41379-019-0343-4","journal-title":"Mod Pathol"},{"key":"4379_CR68","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1097\/PAS.0000000000001715","volume":"45","author":"O Mete","year":"2021","unstructured":"Mete O, Pakbaz S, Lerario AM et al (2021) Significance of alpha-inhibin expression in pheochromocytomas and paragangliomas. Am J Surg Pathol 45:1264\u20131273. https:\/\/doi.org\/10.1097\/PAS.0000000000001715","journal-title":"Am J Surg Pathol"},{"key":"4379_CR69","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/PAS.0000000000001945","volume":"47","author":"TL Fuchs","year":"2023","unstructured":"Fuchs TL, Luxford C, Clarkson A et al (2023) A clinicopathologic and molecular analysis of fumarate hydratase-deficient pheochromocytoma and paraganglioma. Am J Surg Pathol 47:25\u201336. https:\/\/doi.org\/10.1097\/PAS.0000000000001945","journal-title":"Am J Surg Pathol"},{"key":"4379_CR70","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12022-022-09744-y","volume":"34","author":"SL Asa","year":"2023","unstructured":"Asa SL, Mohamed A (2023) Menin loss in pheochromocytoma of multiple endocrine neoplasia type 1. Endocr Pathol 34:156\u2013158. https:\/\/doi.org\/10.1007\/s12022-022-09744-y","journal-title":"Endocr Pathol"},{"key":"4379_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-022-00291-3","volume":"7","author":"LE Oldfield","year":"2022","unstructured":"Oldfield LE, Grzybowski J, Grenier S et al (2022) VHL mosaicism: the added value of multi-tissue analysis. NPJ Genom Med 7:21. https:\/\/doi.org\/10.1038\/s41525-022-00291-3","journal-title":"NPJ Genom Med"},{"key":"4379_CR72","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","volume":"26","author":"LDR Thompson","year":"2002","unstructured":"Thompson LDR (2002) Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26:551\u2013566","journal-title":"Am J Surg Pathol"},{"key":"4379_CR73","doi-asserted-by":"publisher","first-page":"e4661","DOI":"10.1210\/clinem\/dgaa608","volume":"105","author":"H Wachtel","year":"2020","unstructured":"Wachtel H, Hutchens T, Baraban E et al (2020) Predicting metastatic potential in pheochromocytoma and paraganglioma: a comparison of PASS and GAPP scoring systems. J Clin Endocrinol Metab 105:e4661-4670. https:\/\/doi.org\/10.1210\/clinem\/dgaa608","journal-title":"J Clin Endocrinol Metab"},{"key":"4379_CR74","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001190","author":"A Stenman","year":"2018","unstructured":"Stenman A, Svahn F, Hojjat-Farsangi M et al (2018) Molecular profiling of pheochromocytoma and abdominal paraganglioma stratified by the PASS algorithm reveals chromogranin B as associated with histologic prediction of malignant behavior. Am J Surg Pathol. https:\/\/doi.org\/10.1097\/PAS.0000000000001190","journal-title":"Am J Surg Pathol"},{"key":"4379_CR75","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1530\/ERC-13-0494","volume":"21","author":"N Kimura","year":"2014","unstructured":"Kimura N, Takayanagi R, Takizawa N et al (2014) Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 21:405\u2013414. https:\/\/doi.org\/10.1530\/ERC-13-0494","journal-title":"Endocr Relat Cancer"},{"key":"4379_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187398","volume":"12","author":"J-M Koh","year":"2017","unstructured":"Koh J-M, Ahn SH, Kim H et al (2017) Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One 12:e0187398. https:\/\/doi.org\/10.1371\/journal.pone.0187398","journal-title":"PLoS One"},{"key":"4379_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11020225","author":"A Stenman","year":"2019","unstructured":"Stenman A, Zedenius J, Juhlin CC (2019) The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas-a meta-analysis and systematic review of the literature. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11020225","journal-title":"Cancers (Basel)"},{"key":"4379_CR78","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00423-018-1679-9","volume":"403","author":"A Stenman","year":"2018","unstructured":"Stenman A, Zedenius J, Juhlin CC (2018) Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms. Langenbecks Arch Surg 403:785\u2013790. https:\/\/doi.org\/10.1007\/s00423-018-1679-9","journal-title":"Langenbecks Arch Surg"},{"key":"4379_CR79","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1097\/PAS.0000000000002238","volume":"48","author":"Q Li","year":"2024","unstructured":"Li Q, Lan Z, Jiang Y et al (2024) Validation and evaluation of 5 scoring systems for predicting metastatic risk in pheochromocytoma and paraganglioma. Am J Surg Pathol 48:855\u2013865. https:\/\/doi.org\/10.1097\/PAS.0000000000002238","journal-title":"Am J Surg Pathol"},{"key":"4379_CR80","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/jso.27681","volume":"130","author":"C Chun","year":"2024","unstructured":"Chun C, Song L, Xu G et al (2024) Analysis of clinical and pathological characteristics of retroperitoneal paraganglioma and associated prognostic factors. J Surg Oncol 130:47\u201355. https:\/\/doi.org\/10.1002\/jso.27681","journal-title":"J Surg Oncol"},{"key":"4379_CR81","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00428-019-02553-5","volume":"474","author":"C Pierre","year":"2019","unstructured":"Pierre C, Agopiantz M, Brunaud L et al (2019) COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas. Virchows Arch 474:721\u2013734. https:\/\/doi.org\/10.1007\/s00428-019-02553-5","journal-title":"Virchows Arch"},{"key":"4379_CR82","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.surg.2018.05.001","volume":"164","author":"YY Cho","year":"2018","unstructured":"Cho YY, Kwak MK, Lee S-E et al (2018) A clinical prediction model to estimate the metastatic potential of pheochromocytoma\/paraganglioma: ASES score. Surgery 164:511\u2013517. https:\/\/doi.org\/10.1016\/j.surg.2018.05.001","journal-title":"Surgery"},{"key":"4379_CR83","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/biomedicines10061310","volume":"10","author":"M Parasiliti-Caprino","year":"2022","unstructured":"Parasiliti-Caprino M, Bioletto F, Lopez C et al (2022) From SGAP-model to SGAP-score: a simplified predictive tool for post-surgical recurrence of pheochromocytoma. Biomedicines 10:1310. https:\/\/doi.org\/10.3390\/biomedicines10061310","journal-title":"Biomedicines"},{"key":"4379_CR84","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae093","volume":"8","author":"DYV Iguchi","year":"2024","unstructured":"Iguchi DYV, Martins Filho SN, Soares IC et al (2024) Identification of predictors of metastatic potential in paragangliomas to develop a prognostic score (PSPGL). J Endocr Soc 8:bvae093. https:\/\/doi.org\/10.1210\/jendso\/bvae093","journal-title":"J Endocr Soc"},{"key":"4379_CR85","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12022-025-09878-9","volume":"36","author":"E Rapizzi","year":"2025","unstructured":"Rapizzi E, Zanatta L, Santi A et al (2025) Presurgical succinate metastatic risk tool (P-SMART) in paragangliomas. Endocr Pathol 36:33. https:\/\/doi.org\/10.1007\/s12022-025-09878-9","journal-title":"Endocr Pathol"},{"key":"4379_CR86","doi-asserted-by":"publisher","first-page":"852","DOI":"10.4103\/ijpm.ijpm_859_23","volume":"67","author":"A Mondal","year":"2024","unstructured":"Mondal A, Sengupta M, Dey S et al (2024) Clinicopathological study of adrenal pheochromocytoma and extra-adrenal paragangliomas with reference to GAPP and PASS scoring systems. Indian J Pathol Microbiol 67:852\u2013858. https:\/\/doi.org\/10.4103\/ijpm.ijpm_859_23","journal-title":"Indian J Pathol Microbiol"},{"key":"4379_CR87","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000365","author":"CC Juhlin","year":"2022","unstructured":"Juhlin CC, Mete O (2022) Advances in adrenal and extra-adrenal paraganglioma: practical synopsis for pathologists. Adv Anat Pathol. https:\/\/doi.org\/10.1097\/PAP.0000000000000365","journal-title":"Adv Anat Pathol"},{"key":"4379_CR88","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/s41467-025-57595-y","volume":"16","author":"A Flynn","year":"2025","unstructured":"Flynn A, Pattison AD, Balachander S et al (2025) Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles. Nat Commun 16:2632. https:\/\/doi.org\/10.1038\/s41467-025-57595-y","journal-title":"Nat Commun"},{"key":"4379_CR89","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1677\/ERC-09-0316","volume":"17","author":"A Blank","year":"2010","unstructured":"Blank A, Schmitt AM, Korpershoek E et al (2010) SDHB loss predicts malignancy in pheochromocytomas\/sympathethic paragangliomas, but not through hypoxia signalling. Endocr Relat Cancer 17:919\u2013928. https:\/\/doi.org\/10.1677\/ERC-09-0316","journal-title":"Endocr Relat Cancer"},{"key":"4379_CR90","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/modpathol.2015.41","volume":"28","author":"TG Papathomas","year":"2015","unstructured":"Papathomas TG, Oudijk L, Persu A et al (2015) SDHB\/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a multinational study of the European Network for the Study of Adrenal Tumors (ENS@T). Mod Pathol 28:807\u2013821. https:\/\/doi.org\/10.1038\/modpathol.2015.41","journal-title":"Mod Pathol"},{"key":"4379_CR91","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/(SICI)1097-0142(19991015)86:8<1583::AID-CNCR28>3.0.CO;2-#","volume":"86","author":"HM Brown","year":"1999","unstructured":"Brown HM, Komorowski RA, Wilson SD et al (1999) Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: a positive correlation between MIB-1 staining and malignant tumor behavior. Cancer 86:1583\u20131589","journal-title":"Cancer"},{"key":"4379_CR92","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12022-022-09746-w","volume":"34","author":"K Solhusl\u00f8kk H\u00f6se","year":"2023","unstructured":"Solhusl\u00f8kk H\u00f6se K, Stenman A, Svahn F et al (2023) Top2a expression in pheochromocytoma and abdominal paraganglioma: a marker of poor clinical outcome? Endocr Pathol 34:129\u2013141. https:\/\/doi.org\/10.1007\/s12022-022-09746-w","journal-title":"Endocr Pathol"},{"key":"4379_CR93","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/01.MP.0000056982.07160.E3","volume":"16","author":"EE Elder","year":"2003","unstructured":"Elder EE, Xu D, H\u00f6\u00f6g A et al (2003) KI-67 and hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Mod Pathol 16:246\u2013255. https:\/\/doi.org\/10.1097\/01.MP.0000056982.07160.E3","journal-title":"Mod Pathol"},{"key":"4379_CR94","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.prp.2010.01.007","volume":"206","author":"SM Tavangar","year":"2010","unstructured":"Tavangar SM, Shojaee A, Moradi Tabriz H et al (2010) Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma. Pathol Res Pract 206:305\u2013309. https:\/\/doi.org\/10.1016\/j.prp.2010.01.007","journal-title":"Pathol Res Pract"},{"key":"4379_CR95","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF02921490","volume":"5","author":"N Kimura","year":"1994","unstructured":"Kimura N, Miura W, Noshiro T et al (1994) Ki-67 is an indicator of progression of neuroendocrine tumors. Endocr Pathol 5:223\u2013228. https:\/\/doi.org\/10.1007\/BF02921490","journal-title":"Endocr Pathol"},{"key":"4379_CR96","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5114\/pjp.2013.36004","volume":"64","author":"M Bia\u0142as","year":"2013","unstructured":"Bia\u0142as M, Oko\u0144 K, Dyduch G et al (2013) Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas - a comparative study. Pol J Pathol 64:129\u2013135","journal-title":"Pol J Pathol"},{"key":"4379_CR97","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s12022-020-09633-2","volume":"31","author":"JF Powers","year":"2020","unstructured":"Powers JF, Tischler AS (2020) Immunohistochemical staining for SOX10 and SDHB in SDH-deficient paragangliomas indicates that sustentacular cells are not neoplastic. Endocr Pathol 31:307\u2013309. https:\/\/doi.org\/10.1007\/s12022-020-09633-2","journal-title":"Endocr Pathol"},{"key":"4379_CR98","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/j.1365-2559.1986.tb02539.x","volume":"10","author":"HD Schroder","year":"1986","unstructured":"Schroder HD, Johannsen L (1986) Demonstration of S-100 protein in sustentacular cells of phaeochromocytomas and paragangliomas. Histopathology 10:1023\u20131033. https:\/\/doi.org\/10.1111\/j.1365-2559.1986.tb02539.x","journal-title":"Histopathology"},{"key":"4379_CR99","first-page":"484","volume":"115","author":"P Unger","year":"1991","unstructured":"Unger P, Hoffman K, Pertsemlidis D et al (1991) S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas. Arch Pathol Lab Med 115:484\u2013487","journal-title":"Arch Pathol Lab Med"},{"key":"4379_CR100","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s12022-020-09632-3","volume":"31","author":"YY Zhou","year":"2020","unstructured":"Zhou YY, Coffey M, Mansur D et al (2020) Images in endocrine pathology: progressive loss of sustentacular cells in a case of recurrent jugulotympanic paraganglioma over a span of 5 years. Endocr Pathol 31:310\u2013314. https:\/\/doi.org\/10.1007\/s12022-020-09632-3","journal-title":"Endocr Pathol"},{"key":"4379_CR101","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41467-024-55289-5","volume":"16","author":"A Santambrogio","year":"2025","unstructured":"Santambrogio A, Kemkem Y, Willis TL et al (2025) SOX2+ sustentacular cells are stem cells of the postnatal adrenal medulla. Nat Commun 16:16. https:\/\/doi.org\/10.1038\/s41467-024-55289-5","journal-title":"Nat Commun"},{"key":"4379_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01145-8","volume":"9","author":"P Bullova","year":"2025","unstructured":"Bullova P, Cui P, Arceo M et al (2025) Postnatal sustentacular cells as chromaffin progenitors and tumor cells of origin in VHL-related paragangliomas. npj Precision Oncology 9:324. https:\/\/doi.org\/10.1038\/s41698-025-01145-8","journal-title":"npj Precision Oncology"},{"key":"4379_CR103","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrendo.2014.188","volume":"11","author":"J Favier","year":"2015","unstructured":"Favier J, Amar L, Gimenez-Roqueplo A-P (2015) Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol 11:101\u2013111. https:\/\/doi.org\/10.1038\/nrendo.2014.188","journal-title":"Nat Rev Endocrinol"},{"key":"4379_CR104","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1158\/1078-0432.CCR-18-0139","volume":"25","author":"S Job","year":"2019","unstructured":"Job S, Draskovic I, Burnichon N et al (2019) Telomerase activation and ATRX mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma. Clin Cancer Res 25:760\u2013770. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0139","journal-title":"Clin Cancer Res"},{"key":"4379_CR105","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/s41467-023-36769-6","volume":"14","author":"B Calsina","year":"2023","unstructured":"Calsina B, Pi\u00f1eiro-Y\u00e1\u00f1ez E, Mart\u00ednez-Montes \u00c1M et al (2023) Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma. Nat Commun 14:1122. https:\/\/doi.org\/10.1038\/s41467-023-36769-6","journal-title":"Nat Commun"},{"key":"4379_CR106","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1210\/endrev\/bnae005","volume":"45","author":"O Uher","year":"2024","unstructured":"Uher O, Hadrava Vanova K, Ta\u00efeb D et al (2024) The immune landscape of pheochromocytoma and paraganglioma: current advances and perspectives. Endocr Rev 45:521\u2013552. https:\/\/doi.org\/10.1210\/endrev\/bnae005","journal-title":"Endocr Rev"},{"key":"4379_CR107","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12020-022-03218-1","volume":"79","author":"S Ghosal","year":"2023","unstructured":"Ghosal S, Hadrava Vanova K, Uher O et al (2023) Immune signature of pheochromocytoma and paraganglioma in context of neuroendocrine neoplasms associated with prognosis. Endocrine 79:171\u2013179. https:\/\/doi.org\/10.1007\/s12020-022-03218-1","journal-title":"Endocrine"},{"key":"4379_CR108","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1210\/clinem\/dgad149","volume":"108","author":"X Zhong","year":"2023","unstructured":"Zhong X, Su T, Yang Y et al (2023) Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic markers for pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 108:2230\u20132239. https:\/\/doi.org\/10.1210\/clinem\/dgad149","journal-title":"J Clin Endocrinol Metab"},{"key":"4379_CR109","unstructured":"American Joint Committee on Cancer (2017) AJCC cancer staging manual, Eighth edition, corrected at 3rd printing. AJCC, American Joint Committee on Cancer, Chicago, IL."},{"key":"4379_CR110","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.humpath.2020.04.012","volume":"110","author":"LDR Thompson","year":"2021","unstructured":"Thompson LDR, Gill AJ, Asa SL et al (2021) Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Hum Pathol 110:83\u201397. https:\/\/doi.org\/10.1016\/j.humpath.2020.04.012","journal-title":"Hum Pathol"},{"key":"4379_CR111","unstructured":"Mete O, Asa SL, Erickson LA, et al. (2025) The College of American pathologist\u2019s protocol for the examination of specimens from patients with paraganglioma and pheochromocytoma. Version: 1.0.0.0. Available at https:\/\/www.cap.org\/protocols-and-guidelines\/cancer-reporting-tools\/cancer-protocol-templates"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04379-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04379-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04379-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:53:50Z","timestamp":1770274430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04379-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4379"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04379-w","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}